Clinical Trials Recruiting RSS

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
Source: Clinical Trials Recruiting Published on 2024-10-28
An Observational Study Using The LumAssure Device In Participants Undergoing Assessment Of Skin Conditions.
Source: Clinical Trials Recruiting Published on 2024-10-28
A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Hyaluronidase (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
Source: Clinical Trials Recruiting Published on 2024-07-16
Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts
Source: Clinical Trials Recruiting Published on 2024-07-09
A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma
Source: Clinical Trials Recruiting Published on 2024-07-03
Evaluation of a Simple-Prep Controlled Embolic
Source: Clinical Trials Recruiting Published on 2024-06-11
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Advanced or Metastatic Solid Tumors
Source: Clinical Trials Recruiting Published on 2024-05-24
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
Source: Clinical Trials Recruiting Published on 2024-04-10
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Source: Clinical Trials Recruiting Published on 2024-04-09
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Source: Clinical Trials Recruiting Published on 2024-04-08
A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)
Source: Clinical Trials Recruiting Published on 2024-04-03
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Source: Clinical Trials Recruiting Published on 2024-03-15
A Study of Pembrolizumab (MK-3475) Plus V940 in Participants With Bladder Cancer Post-Radical Resection (V940-005)
Source: Clinical Trials Recruiting Published on 2024-03-12
A Study of (Neo)Adjuvant V940 and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
Source: Clinical Trials Recruiting Published on 2024-03-06
A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study
Source: Clinical Trials Recruiting Published on 2024-03-04